Jeffrey Hackman is Chief Executive Officer of Fennec Pharmaceuticals Inc. (FENC). The company reported total compensation of $1,722,154 for fiscal year 2025.
| Salary | $586,343 |
|---|---|
| Bonus | $45,833 |
| Stock awards | $887,100 |
| Option awards | $202,878 |
| Non-equity incentive plan | $0 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $0 |
| Total | $1,722,154 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Fennec Pharmaceuticals Inc. filed April 28, 2026, accession 0001104659-26-050339.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Robert Andrade | Chief Financial Officer | $1,873,024 |
| Jeffrey Hackman this page | Chief Executive Officer | $1,722,154 |
| Pierre Sayad | Chief Medical Officer | $775,081 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Fennec Pharmaceuticals Inc. compensation brief.
Jeffrey Hackman's compensation sits inside Fennec Pharmaceuticals Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.